Prescription opioid analgesics for pain management in Australia: 20 years of dispensing

Internal Medicine Journal

Volumn 46, Issue 8, 2016, Pages 955-963

  Islam, M M ^a   McRae, I S ^a   Mazumdar, S ^a,b   Taplin, S ^c   McKetin, R ^a  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b UNIVERSITY OF CANBERRA   (Australia)

^c AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

Author keywords

analgesics; daily defined dose; opioid analgesics; opioid dispensing; pain medicine; prescription opioid

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; BUPRENORPHINE; CODEINE; CODEINE PHOSPHATE; DEXTROMORAMIDE; DEXTROPROPOXYPHENE NAPSILATE; DIHYDROCODEINE; FENTANYL; HYDROMORPHONE; HYOSCYAMINE; MORPHINE; NALOXONE; OPIATE; OXYCODONE; PARACETAMOL; PENTAZOCINE; PETHIDINE; TRAMADOL;

ANALGESIA; ARTICLE; AUSTRALIA; DRUG FORMULATION; PRESCRIPTION; PRIORITY JOURNAL; SEASONAL VARIATION;

EID: 84983491070     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12966     Document Type: Article

References (37)

1. International Narcotics Control Board. Report of the International Narcotics Control Board for 2011. New York (NY): United Nations; 2012.
2. Roxburgh A, Bruno R, Larance B, Burns L. Prescription of opioid analgesics and related harms in Australia. Med J Aust 2011; 195: 280–4.
3. Blanch B, Pearson SA, Haber PS. An overview of the patterns of prescription opioid use, costs and related harms in Australia. Br J Clin Pharmacol 2014; 78: 1159–66.
4. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. The Journal of Pain: Official Journal of the American Pain Society 2009; 10: 113–30.
5. Islam MM, McRae IS. An inevitable wave of prescription drug monitoring programs in the context of prescription opioids: pros, cons and tensions. BMC Pharmacology & Toxicology 2014; 15: 46.
6. Hallinan R. Prescribing a disaster. MJA Insight 2011 Oct 31 [cited 2015 Jun]. Available from URL: https://www.mja.com.au/insight/2011/41/richard-hallinan-prescribing-disaster
7. Hojsted J, Sjogren P. Addiction to opioids in chronic pain patients: a literature review. Eur J Pain 2007; 11: 490–518.
8. Mazumdar S, McRae IS, Islam MM. How can geographical information systems and spatial analysis inform a response to prescription opioid misuse? A discussion in the context of existing literature. Curr Drug Abuse Rev 2015; 8: 104–110.
9. Nielsen S, Bruno R, Degenhardt L, Stoove MA, Fischer JA, Carruthers SJ et al. The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids. Med J Aust 2013; 199: 696–9.
10. Silversides A. Australia moves to combat the misuse of prescription opioids. BMJ 2011; 342: d1345.
11. The Royal Australasian College of Physicians. Prescription Opioid Policy: Improving Management of Chronic Non-Malignant Pain and Prevention of Problems Associated with Prescription Opioid Use. Sydney: The Royal Australasian College of Physicians; 2009.
12. Drugs and Crime Prevention Committee. Inquiry Into the Misuse/Abuse of Benzodiazepines and Other Forms of Pharmaceutical Drugs in Victoria: Final Report. Melbourne: Drugs and Crime Prevention Committee, Parliament of Victoria; 2007.
13. Hollingworth SA, Symons M, Khatun M, Loveday B, Ballantyne S, Hall WD et al. Prescribing databases can be used to monitor trends in opioid analgesic prescribing in Australia. Aust N Z J Public Health 2013; 37: 132–8.
14. World Health Organization. Guidelines for ATC Classification and DDD Assignment. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 2012.
15. Department of Human Services. What is the PBS? Canberra: Australian Government [cited 2012 Jan 15]. Available from URL: http://www.medicareaustralia.gov.au/provider/pbs/education/pbs-and-you-manual/what.jsp
16. Department of Human Services. PBS Frequently Asked Questions. Canberra: Australian Government [cited 2015 Jan 15]. Available from URL: http://www.pbs.gov.au/info/general/faq
17. Australian Government's Department of Health. Australian Statistics on Medicines 2010. Canberra: Australian Government [cited 2015 Jan 15]. Available from URL: http://www.pbs.gov.au/info/statistics/asm/asm-2010
18. Islam MM, Conigrave KM, Day CA, Nguyen Y, Haber PS. Twenty-year trends in benzodiazepine dispensing in the Australian population. Intern Med J 2014; 44: 57–64.
19. Carpenter A, Islam MM, Yen L, McRae I. Affordability of out-of-pocket health care expenses among older Australians. Health Policy 2015; 119: 907–14.
20. Wild CJ, Seber GAF. Time series. In: Chance Encounters: A First Course in Data Analysis and Inference. New York: John Wiley & Sons; 1999.
21. Australian Institute of Health and Welfare. All Cancers. 2015 [cited 2015 Jul 29]. Available from URL: http://www.aihw.gov.au/cancers/all-cancers/
22. Australian Bureau of Statistics. Characteristics of Bodily Pain in Australia. 2012 [cited 2015 Jul 29]. Available from URL: http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/4841.0Chapter12011
23. Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO 2008; 19: 1985–91.
24. Johnston J, Cogan J, Choinière M, Celly A. The patient pain manifesto: a novel approach to changing pain assessment and management of hospitalized patients. Canadian Pain Society Annual Conference, Toronto. Pain Res Manag 2003; 8: 24B.
25. Heitz JW, Witkowski TA, Viscusi ER. New and emerging analgesics and analgesic technologies for acute pain management. Curr Opin Anaesthesiol 2009; 22: 608–17.
26. Van Zee A. The promotion and marketing of oxycontin: commercial triumph, public health tragedy. Am J Public Health 2009; 99: 221–7.
27. Olesen AE, Staahl C, Arendt-Nielsen L, Drewes AM. Different effects of morphine and oxycodone in experimentally evoked hyperalgesia: a human translational study. Br J Clin Pharmacol 2010; 70: 189–200.
28. Shand FL, Campbell G, Hall W, Lintzeris N, Cohen M, Degenhardt L. Real-time monitoring of Schedule 8 medicines in Australia: evaluation is essential. Med J Aust 2013; 198: 80–1.
29. National Drug and Alcohol Research Centre. A review of opioid prescribing in Tasmania: a blueprint for the future. Sydney: University of New South Wales; 2012.
30. Stafford J, Burns L. Australian drug trends 2010: findings from the Illicit Drug Reporting System (IDRS). Sydney: National Drug and Alcohol Research Centre; 2010.
31. Australian Government's Department of Health and Ageing. Australian Statistics on Medicines. Canberra: Pharmaceutical Benefit Scheme, Department of Health; 2008.
32. Dart RC, Surratt HL, Cicero TJ, Parrino MW, Severtson SG, Bucher-Bartelson B et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 2015; 372: 241–8.
33. Dobbin M. Misuse of pharmaceutical drugs in Australia. Victoria: Department of Health; 2009.
34. van Amsterdam J, van den Brink W. The misuse of prescription opioids: a threat for Europe? Curr Drug Abuse Rev 2015; 8: 3–14.
35. Cousins MJ, Brydon L. Unrelieved pain: are we making progress? Shared education for general practitioners and specialists is the best way forward. Med J Aust 2014; 201: 379–80.
36. Finch JW. Challenges of chronic pain management: public health consequences and considered responses. N C Med J 2013; 74: 243–5.
37. Islam MM, McRae IS. Real-time prescription drug monitoring program in Australia: we should be ready. Drug Alcohol Rev 2015; 34: 344–5.